Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

Early-career physician-scientists receive major support from Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation has named five new Damon Runyon Clinical Investigators.

14 Jul 2025

New immunotherapy targets leukemia at its root

Researchers at MUSC Hollings Cancer Center have identified a signaling loop involved in the growth and persistence of leukemia cells – and developed a novel immunotherapy that can disrupt that loop to boost immune function and improve survival.

14 Jul 2025

Blood test can reveal early signs of leukemia without bone marrow sampling

What if a blood test could reveal the pace of our aging – and the diseases that may lie ahead? The labs of Profs. Liran Shlush and Amos Tanay at the Weizmann Institute of Science have been conducting in-depth studies into the biology of blood to better understand the aging process and why some people become more susceptible to disease over the years.

27 Jun 2025

Epigenetic enzyme SETD1B drives aggressive growth in acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive cancer affecting the blood and bone marrow that progresses rapidly, making immediate treatment essential.

26 Jun 2025

Scientists identify novel combination therapy approach to treat pediatric acute myeloid leukemia

Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia (AML).

20 Jun 2025

New drug combination shows high remission rates in acute myeloid leukemia

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid leukemia (AML) showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger Comprehensive Cancer Center and 11 other sites nationwide.

13 Jun 2025

Study explains why some AML patients do not respond to standard treatment

An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn't work for everyone.

21 May 2025

Combination of two drugs shows promise in treating B-cell acute lymphoblastic leukemia

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be particularly difficult to treat in older patients, according to Cambridge scientists.

20 May 2025

Taurine identified as a key regulator of myeloid cancers

A new scientific study identified taurine, which is made naturally in the body and consumed through some foods, as a key regulator of myeloid cancers such as leukemia, according to a paper published in the journal Nature.

14 May 2025

Routine molecular monitoring doubles survival in high-risk AML subtypes

A highly sensitive bone marrow test could double survival rates for some groups of younger adults with Acute Myeloid Leukemia (AML) by helping doctors identify if they might relapse up to three months earlier.

29 Apr 2025

New approach targets cell surface protein to treat leukemia and solid tumors

In 2021, research led by Ryan Flynn, MD, PhD, and his mentor, Nobel laureate Carolyn Bertozzi, PhD, opened a new chapter in biology, characterizing a new kind of player on the cell surface: glycoRNAs.

23 Apr 2025

Drug-carrying DNA aptamers offer dual action against leukemia stem cells

Drug-carrying DNA aptamers can deliver a one-two punch to leukemia by precisely targeting the elusive cancer stem cells that seed cancer relapses, researchers at the University of Illinois Urbana-Champaign report.

3 Apr 2025

New drug target identified for treating acute myeloid leukemia

A team of scientists from The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has identified a promising new drug target for acute myeloid leukemia (AML), a deadly blood cancer with a five-year survival rate of just 30%, according to the National Cancer Institute.

2 Apr 2025

HLA-DRB1 molecule can be a potential target in treating acute myeloid leukemia

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells.

1 Apr 2025

New supercharged CAR-T cell therapy shows promise against resistant cancers

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder for prior CAR-T therapies to detect and fight.

10 Mar 2025

Study identifies key role of JMJD1C in acute myeloid leukemia

Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of immature myeloid cells.

3 Mar 2025

Advancements in molecular diagnostics for hematopoietic and lymphocytic neoplasms

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.

27 Feb 2025

Innovative combination of treatments effectively kills acute myeloid leukemia cells

Scientists at VCU Massey Comprehensive Cancer Center have identified an innovative combination of treatment strategies that work collaboratively to effectively kill acute myeloid leukemia (AML) cells, a frequently incurable form of cancer.

27 Feb 2025

PFAS exposure via drinking water contamination may play a role in childhood cancer risk

A study led by the Joe C. Wen School of Population & Public Health at the University of California, Irvine has revealed possible links between exposure to per- and polyfluoroalkyl substances in drinking water and an increased risk of certain childhood cancers.

26 Feb 2025